The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM).
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); Roche TCRC (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for MPF assay from Morphotek (approximately $700/year)
 
Dean Fennell
No Relationships to Disclose
 
Arnaud Scherpereel
No Relationships to Disclose
 
Anna K. Nowak
Consulting or Advisory Role - Aduro Biotech; Morphotek
Research Funding - Boehringer Ingelheim (Inst)
Travel, Accommodations, Expenses - Amgen
 
Joachim Von Pawel
No Relationships to Disclose
 
Silvia Novello
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Lilly; Merck Sharp & Dohme; Roche/Genentech
 
Megan McLaughlin
Employment - Morphotek
 
Kimberly Hoffman
Employment - Morphotek
 
Bruce A. Wallin
Employment - Morphotek
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie (I)
Consulting or Advisory Role - Morphotek
Travel, Accommodations, Expenses - Morphotek